Delving into the Latest Updates on RG002C0106 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms

RG002C0106

Target

C3

Action

inhibitors

Mechanism

C3 inhibitors(Complement C3 inhibitors)

Therapeutic Areas

Immune System DiseasesUrogenital DiseasesOther Diseases+ [1]

Active Indication

Glomerulonephritis, IGAGlomerular diseaseAtypical Hemolytic Uremic Syndrome+ [2]

Inactive Indication-

Originator Organization

Rigerna Therapeutics Co. Ltd

Active Organization

Suzhou Xuanjing Biotechnology Co., Ltd.Rigerna Therapeutics Co. Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous injection of RG002C0106 between trial participants with normal renal function and those with mild to moderate renal impairment.

Start Date15 Mar 2026

Sponsor / Collaborator

Rigerna Therapeutics Co. Ltd

NCT07305974

/ RecruitingPhase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic/Pharmacodynamic Characteristics of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.

Start Date08 Sep 2025

Sponsor / Collaborator

Rigerna Therapeutics Co. Ltd

NCT06494527

/ Active, not recruitingPhase 1

A Randomized, Double-blind, Placebo-controlled, Single/Multiple Ascending Dose, Phase 1 International Multi-center Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics of RG002C0106 Injection in Healthy Adults

This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and PK/PD profiles of RG002C0106 injection in healthy adult subjects. The study will be divided into the following parts:
Part A, conducted : SAD stage Part B, conducted: MAD stage

Start Date18 Oct 2024

Sponsor / Collaborator

Rigerna Therapeutics Co. Ltd

100 Clinical Results associated with RG002C0106

Login to view more data

100 Translational Medicine associated with RG002C0106

Login to view more data

100 Patents (Medical) associated with RG002C0106

Login to view more data

100 Deals associated with RG002C0106

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, IGA	Phase 2	China	Suzhou Xuanjing Biotechnology Co., Ltd.	28 Aug 2025
Glomerular disease	Phase 1	China	Suzhou Xuanjing Biotechnology Co., Ltd.	18 Oct 2024
Atypical Hemolytic Uremic Syndrome	IND Approval	China	Suzhou Xuanjing Biotechnology Co., Ltd.	29 Nov 2025
Cold Agglutinin Disease	IND Approval	China	Suzhou Xuanjing Biotechnology Co., Ltd.	29 Nov 2025
Hemoglobinuria, Paroxysmal	IND Approval	China	Suzhou Xuanjing Biotechnology Co., Ltd.	29 Nov 2025